1971; Melvin et al., 1972) but we have studied several products of breast neoplasia and found them to be released in insufficient quantities to be sensitive guides of tumour burden (Cove et al., 1979a,b; Woods et al., 1 979) .
Inflammatory disease can be monitored by serial estimations of serum proteins (McConkey et al., 1972) . Raised levels are detectable in patients with colonic (Milford Ward et al., 1977) , bronchial (Bradwell, 1979) and breast neoplasia (Coombes et al., 1977) and a rise in acute-phase protein precedes clinical evidence of recurrent bronchial cancer by up to 10 months (Bradwell, 1] 979). We have studied 5 serum proteins in patients who were parAcceptedI 7 January 1981 ticipating in a trial of adjuvant chemotherapy and who developed recurrent breast cancer.
All patients entered into the chemotherapy trial were women under the age of 65 who had no serious intercurrent illness, with operable breast cancer and no clinical or radiological evidence of metastasis at the time of mastectomy. Patients were randomized into treatment or untreated control groups, and followed at 3-monthly intervals by clinical examination and biochemical profile, and at 6-monthly intervals by skeletal survey, chest X-ray and bone scan. Recurrence of tumour was diagnosed histologically or radiologically. Serum for tumour-marker studies was taken preoperatively and at the time of recurrence. Serial samples at 3-monthly intervals after mastectomy were obtained from patients attending 4 of the 8 follow-up centres. Serum was frozen within 4 h of venesection and stored at -40°C for 3-24 months.
The proteins were estimated in sera collected from 50 patients when the recurrent tumour was identified. Of the 35 patients with one or more elevated protein concentrations, stored serum samples taken at 3-monthly intervals from the time of mastectomy were available for 21. In the present study, serum protein concentrations at recurrence are compared with levels 3 months earlier and 3 months Table I . The serum proteins were estimated by the Mancini radial immunodiffusion method (Mancini et al., 1965) . The antisera and standard proteins were obtained from Seward Laboratories (C-reactive protein (CRP)) and Hoechst Pharmaceuticals (cilantitrypsin, haptoglobin, orosomucoid and prealbumin) and the upper limits of normal were taken as 10 mg/l, 4 g/l, 2-6 g/l, 1-4 g/l and 0'4 g/l respectively (Behring, 1979) . The lower limit of normal for prealbumin was taken as 0-1 g/l. The inter-and intra-assay coefficients of variation were less than 500.
The mean protein concentrations and the number of patients with raised levels are reported (Table II) (Table II) . Pre-albumin concentrations were normal in all patients. Protein abnormalities did not appear to be associated with the site of recurrence or treatment with chemotherapy (data not given).
In 21 patients, all of whom had raised levels of one or more proteins at the time of recurrence, the concentrations of CRP, oal-antitrypsin, haptoglobin and orosomucoid were compared from 3 months after mastectomy to recurrence, and from 3 months before recurrence to recurrence (Table III) . There was no significant rise in any of the mean protein concentrations despite clinical progression of disease. In patients with protein levels above the normal range there was no consistent change during follow-up. For example, from 3 months postoperatively to the time of recurrence, although oal-antitrypsin levels rose in 9 patients they fell in 2, remained static above the normal range in 8 and were within the normal range in 2 (Table III) . Similar variability was found for all 4 proteins and for both follow-up periods, and could not be accounted for by the site of recurrence or treatment with chemotherapy.
In some patients serial 3-monthly pro- (Cove et al., 1979b; Coombes et al., 1977; Franchimont et al., 1976) of patients with advanced disease have raised serum levels of one or more tumour-associated substances, suggesting that a combination of parameters might be a more sensitive guide of tumour load. In a previous report we found haptoglobin concentrations were frequently (40%0) raised in patients with advanced breast cancer, but usually within the normal range in those with local disease (Cove et al., 1979b) . Coombes et al. (1977) reported raised levels of CRP, haptoglobin, orosomucoid and al-antitrypsin in 87%, 38%, 75%0 and 38% respectively of 17 patients with advanced breast cancer. Pettingale et al. (1977) found only one (32-glycoprotein) of 10 plasma proteins to be raised in patients with local breast cancer, comparedc with patients who had benign breast disease. Patients were followed up for a (Coombes et al., 1980) breast cancer. The main aim of this study, however, was not to define the prevalence of protein abnormalities, but to determine whether protein levels changed appropriately with tumour growth during follow-up and could be of value as tumour markers to predict recurrence. During follow-up no overall rise in the concentration of any protein was found, despite clinical or radiological appearance of tumour; nor did we find falls in pre-albumin levels, reported to give information complementary to CRP in other diseases (Buckell et al., 1979) . Levels above the normal range did not rise consistently either from 3 months after operation or from 3 months before recurrence up to the time of recurrence, suggesting that factors other than tumour load are also important in determining the concentrations of these proteins. Unless these factors can be defined and allowed for, our results leave little doubt that estimation of these 5 serum proteins has no place in the management of patients during follow-up after mastectomy.
